In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly
The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
Reuters4d
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...